@article{JTD23297,
author = {Ying Jiang and Qun Luo and Qian Han and Junting Huang and Yonger Ou and Miao Chen and Yu Wen and Silas Sethiel Mosha and Kuimiao Deng and Rongchang Chen},
title = {Sequential changes of serum KL-6 predict the progression of interstitial lung disease},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {8},
year = {2018},
keywords = {},
abstract = {Background: Interstitial lung disease (ILD) is a slowly progressing fatal fibrotic lung disease with a widely variable clinical course and a poor prognosis. Clinicians and patients would benefit from a highly efficient and accurate predictor for ILD. The purpose of this study was to evaluate whether blood biomarkers can predict ILD progression.
Methods: In this study, 85 patients diagnosed as having ILD at the Guangzhou Institute of Respiratory Health participated, including 20 patients with idiopathic pulmonary fibrosis (IPF). During the mean follow-up time of 12 months, every patient was examined during four or five visits in our center. Serum samples were collected at baseline, and after 1, 2, 6, and 12 months and tested for the Klebs von den Lungen-6 (KL-6) concentration. Dynamic fluctuations in this biomarker concentration were examined using a logistic regression model to see if they reflected the progression of ILD.
Results: The baseline levels of serum KL-6 in the ILD patients were significantly increased compared to healthy controls. Serum KL-6 levels were significantly elevated in patients with progression of disease (1,985.2±1,497.8 vs. 1,387.6±1,313.1 µg/mL; P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/23297}
}